20 40% 15% 70 90% 1987 1998 1 63 (24 89) 50 , 21 가 34 가 29 , 64.9% 16 15.0%, 2 5.1% 가 (n=27)33 10 (p=0.0018).가 (n=7)16 (p = 0.0438).가 가 가 20 40% 가 3,4) 1987 1 1998 1 가 가 63 (24 89) 가 50 , 가 21 . 48 (67.6%) 가

(2)

1998

1999

10 18

1999


12 1

3 :			
22 , 14 , 8 ,		34 (47.9%), 가 29 (40.8%),	. 가 14
1, 3.		(19.7%), 7 14 (19.7%)	,
가	가 32	(8), (7), (6),	(6)
	7 32		
(45.1%)		(Table 2).	ECOG
가 39 (54.9%) . 가		1	l 12 , 47 l 1
28 (87.5%) 가			
3 , 1	16		
가 , ,		41 (59.4%)	
가 20 ((51.3%),	28 (40.6%)	
5 (12.8%), 5 (12.8%), 2 (5.1%)), ,	가 가 37 (53.6%),	가 32
, , , , ,		(46.4%) (Table 1).	
1	8 ,		
6, 5, 1.	ο,	2.	
0, 5, 1.	가 27	64	
(20.00)	7r 21	01	
(38.0%) , 2 (2.8%) ,			
가 42 (59.1%) , , , ,	,	Table 1. Palents Characteristics	
2 , , , 1 (
Table 1).			
가		Age	
가 17		Median (range) (years)	63 (25 89) 50:21
10		M:F ratio Perfomance status (ECOG)	30.21
. 8 ,		1	5 (7.0%)
가 7 , 가	4 2	2	53 (74.7%) 12 (16.9%)
		3 4	12 (10.9%)
가	15	Primary site	
(: 2 92) .	13	Lung Breast	48 (67.6%) 5 (7.0%)
	EC 1000V	Colorectal	5 (7.0%)
가 (Linear accelerator, NI		Unknown	4 (5.6%)
Japan) 30 Gy 2	10	Others Brain metastasis on initial diagnosis	9 (127%)
•		Yes	32 (45.1%)
	가	No Extracranial metastases	39 (54.9%)
Kaplan-Meier log ranl	k test	Yes	42 (592%)
, ,		Bone	42 (3)270) 27
, (Performance status, PS),		Lung Liver	15
,		Adrenal gland	12 4
p<0.05		Skin	4
1		No Unknown	27 (38.0%)
		No. of brain metastatic lesions	2 (2.8%)
		Single Multiple	37 (52.1%)
		Treatment method	34 (47.8%)
		Complete WBRT alone	54 (76.0%)
		Incomplete of WBRT Surgical resection + WBRT	10 (14.1%)
1.		August 10000001 TIAC	7 (99%)
2		WBRT: whole brain radiation therapy	
가			

가

Table 2 Orical Manifestations of Brain Metastases in Sold Turnors

Symptoms & Signs	No	%
Headache & Dizziness	34	47.9
Motor weakness	29	40.8
Mental change	14	19.7
Nausea & Vomiting	14	19.7
Visual disturbance	8	11.2
Speech disturbance	7	9.8
Personality change	6	8.4
Memory disturbance	6	8.4
Urinary incontinence	4	5.6
Seizure	3	4.2
Facial palsy	3	4.2
Paresthesia	2	2.8
Dysmetria	1	1.4
Anosmia	1	1.4
Polyuria & Polydipsia	1	1.4



15.0%, 2 5.1% . 198 , 1 7 176 (Fig. 1).

30 Gy 16 , 1 14.2% , 10 3 6 .

(p=0.0250). 7\ (n=37) 16

(p=0.0438)(Fig. 2).




Fig. 1. Overall survival curve of the patients with brain metastases (n=71).




Fig. 2. The difference of survival curve between surgery plus whole brain radiation therapy (WBRT) (n=7) and WBRT alone (n=30) in patients with single brain metastasis.

3. (Table 3). 1 2 가 **ECOG** 16 17.2% 3 4 11 , 1 5.6% (p=0.2313).가 가 가 27 , 1 18.4% 가 12 , 1

Table 3. Prognostic Variables

*whole brain radiation therapy

	Median Survival (weeks)	One year Survival (%)	<i>p</i> Value
	16	14.2	0.0250
Treatment	3	0	0.020
Complete WBRT [*] alone Incomplete WBRT [*]	40	39.8	
Surgery + WBRT	16	14.2	0.0438
Treatment on single metastasis WBRT alone	40	39.8	0.0436
Surgery + WBRT*	18	12.4	0.207
Age	15	15.9	0.3867
< 65			
65	10	19.3	0.8860
Sex	25	4.4	0.0000
Male			
Female	16	17.2	0.2212
Performance Status(ECOG)	11	5.6	0.2313
1,2 3,4			
Primary Cancer Site	15	16.0	0.1705
	23	0	0.1705
Lung Breast	8	0	
Colorectal	10	21.9	
Unknown			
Initial brain metastasis	27	18.4	
Yes	12	11.5	0.0692
No Enter remainless at a facility	10	6.4	
Extracranial metastasis Yes	33	27.9	0.0018
No			0.0016
Number of brain metastasis	18	18.1	
Single Multiple	12	11.1	0.2079

11.5% (p=0.0692).
7h 7h
7h 33 ,1 27.9%
7h 7h 10
,1 6.4% (p=0.0018) (Fig. 3).

7†
10 ,
48%,
15%, 11%, 9%, 5%
, 1, 2) , , , ,




Fig. 3. The difference of survival curve between the patients with extracranial metastases (n=42) and the patients with brain metastases alone (n=27).

. 42 53%, 27 40%, 31%, 15 20%, 17 20%, 10% , , , ,

가 90% 50% 70 .7) 1 65% 64.9% 3 9 1 9% 16% 3, 8) 16 , 1 15.0%

7†
Radiation Therapy Oncology Group (RTOG) 20 Gy/1 40

5가 Gy/4 10 12 Gy 1, 2 4 10 .9) 가 가 10) 11) 가 가 30 Gy 10 10 30 Gy 4 가 12) 가 4 gamma-knife (stereotactic 13) radiosurgery) 가 가 가 14, 15) 가 7 40 가 가 8, 16, 17) 가 가 , 60 15, 18) 가 가 가 1 가 2 가

- , , .
 - Markesbery WR, Brooks WH, Gupta GD, et al. Treatment for patients with cerebral metastases. Arch Neurol 1978; 35: 754-756
 - Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980; 7:529-541
 - Posner JB. Management of central nervous system metastases. Semin Oncol 1977; 4:81-91
 - Posner JB. Management of brain metastases. Rev Neurol 1992; 148:477-487
 - Sen M, Demiral AS, Cetingos H, et al. Prognostic factors on lung cancer with brain metastasis. Radiother Oncol 1996; 46:33-38
 - Coia LR. The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992; 23:229-238
 - 7. Hoskin P, Crow J, Ford H. The influence of extent and local management on the overcome of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 1990; 19:111-115
 - Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6:1-9

3 :

- 9. Borgelt B, Gelber R, Larson M, et al. Ultra-rapid high dose irradiation for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981; 7:1633- 1638
- Sause W, Scott C, Krisch R, et al. Phase I/II trial of accelerated fractionation in brain metastases RTOG 85-28. Int J Radiat Oncol Biol Phys 1993; 26:653-657
- 11. Kamarnicky LT, Phillips TL, Martz K, et al. A randomized phase Ill protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases(RTOG-7916). Int J Radiat Oncol Biol Phys 1991; 20:53-58
- Cooper JS, Steinfield A, Lerch IA. Cerebral metastases: value of reirradiation in selected patients. Radiology 1990; 174:883-885
- Loeffler JS, Kooy HM, Were PW, et al. The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Onc ol 1990; 8:576-582
- Patchell RA, Tibbs PA, Walsh JW. et al. A randomized trial of surgery in the treatment of single metastases. N Engl J Med 1990; 322:494-500
- 15. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys

1994; 29:711-717

- 16. Diener-West M, Dobbins TW, Phillips TL, et al. Identification of an optimal subgroup for treatment evaluation of patients with brain metastas es using RTOG study 7916. Int J Radiat Oncol Biol Phys 1989; 16:669-673
- 17. Park YG, Chun M, Hong YS. Symposium on the management of brain metastasis. Proc Kor Assoc Cancer 1999; 25:21-23
- **18. Galicich JH, Sundaresan N, Arbit E, et al.** Surgical treatment of single brain metastasis: factors associated with survival. Cancer 1980; 45:381-386

Abstract

The Role of Radiotherapy in Patients with Brain Metastasis

Soon Nam Lee, M.D.*, Mi-Soon Choo, M.D.*, Kyung-Ja Lee, M.D.†, and Eunmi Nam, M.D.‡

*Departments of Internal Medicine and [†]Radiation Oncology, College of Medicine, Ewha Womans University [‡]Department of Internal Medicine, College of Medicine, Sung Kyun Kwan University, Samsung Medical Center

<u>Purpose</u>: Brain metastases are the most frequent metastatic neurologic complication of systemic cancer. Even if the prognosis of brain metastases is grave, with available treatments, most patients experience effective palliation of neurologic symptoms and meaningful extension of life. We evaluated the clinical features and prognost ic factors of the patients who were diagnosed as solid tumors with brain metastasis and received radiotherapy for brain metastases.

Materials and Methods: Between January 1987 and January 1998, 71 patients with brain metastases from solid malignancy were included. We reviewed neurologic symptoms and signs of patients and evaluated improvement of neurologic symptoms and signs. Survival durations after brain metastasis were analysed according to several factors such as age, performance status, primary malignancies, the presence of brain metastasis at initial diagnosis of primary tumor, multiplicity of brain metastass, the presence of metastases other than brain, and treatment method

Results: Frequent symptoms associated with brain metastasis were headache (47.9%), motor weakness (40.8%), nausea and vomiting (19.7%) and mental change (19.7%). Palliation of these symptoms was accomplished in 64.9% of cases. The overall median survival time was 16 weeks and 1- and 2-year survival rates were 15.0% and 5.1% respectively. Patients without extracranial metastases (n=27) had longer median survival than patients with extracranial metastases (33 weeks vs 10 weeks, p=0.0018). In patients with single brain metastasis (n=37), the median survival time was longer in patients treated with surgery plus radiotherapy than in patients treated with radiotherapy alone (40 weeks vs 16 weeks, p=0.0438).

<u>Conclusion</u>: Patients who has brain metastases only constitute a prognostically favorable group and they may be benefited from radiotherapy and surgery if indicated.

Key Words: Brain metastases, Radiation therapy, Prognostic factors